vTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief Financial Officer as Company Reinitiates Phase 3 Trial of Oral T1D Adjunctive Therapy to Insulin

Core Viewpoint - vTv Therapeutics Inc. has appointed Dr. Michael Tung as Executive Vice President and Chief Financial Officer, which is a strategic move as the company reinitiates its CATT1 Phase 3 trial for cadisegliatin, a potential treatment for type 1 diabetes [1][2] Company Overview - vTv Therapeutics Inc. is a late-stage biopharmaceutical company focused on developing oral small molecule drug candidates for diabetes and other chronic diseases [3] - The company's clinical pipeline is led by cadisegliatin, currently in a Phase 3 trial, which is being investigated as a potential first-in-class oral glucokinase activator for type 1 diabetes [3][4] Appointment of Dr. Michael Tung - Dr. Tung brings over 20 years of experience in finance, corporate strategy, investor relations, and business development within the biopharmaceutical industry [2] - His previous roles include Chief Financial Officer at AdvanCell Pty Limited and senior positions at FibroGen Inc. and Aclaris Therapeutics [2] - Dr. Tung holds degrees in economics and biology from The George Washington University and an M.D./M.B.A. from Tufts University School of Medicine [2] Cadisegliatin Details - Cadisegliatin (TTP399) is a novel oral small molecule that selectively activates glucokinase in the liver, aimed at improving glycemic control in type 1 diabetes [4] - Non-clinical studies indicate that cadisegliatin increases glucokinase activity independently from insulin, supporting its clinical investigation [4]